Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Polyp-Fighting drug falls short in rare cancer syndrome trial

NCT ID NCT05223036

First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 31 times

Summary

This study tested a daily pill called obeticholic acid (OCA) in 15 people with familial adenomatous polyposis (FAP), a genetic condition that causes hundreds of polyps in the intestines and raises cancer risk. The goal was to see if OCA could safely shrink the number of polyps in the small bowel and colon. The trial was stopped early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Cleveland Clinic Foundation

    Cleveland, Ohio, 44195, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Mayo Clinic in Arizona

    Scottsdale, Arizona, 85259, United States

  • University of Kansas Cancer Center

    Kansas City, Kansas, 66160, United States

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, 48109, United States

  • University of Puerto Rico

    San Juan, 00936, Puerto Rico

Conditions

Explore the condition pages connected to this study.